The Ebola epidemic in West Africa has claimed many lives and will last for months. In the US, a vaccine trial with adults begins now. A 100-percent cure, even in advanced cases has been achieved in animal studies. Use in Africa is in the stars.
A new Ebola vaccine to be in the next few days in the United States for the first time people tested. The Mediterranean had been developed by the US Institute for allergies and infectious diseases (NIAID) and the pharmaceutical manufacturer GlaxoSmithKline, together, informed the US health authority, the NIH (National Institutes of Health). The Experiments were designed in such a way that the participants could not be infected with the life-threatening disease. At the beginning of such Tests, it is about the compatibility of an Agent. But up to a mission in Africa, it is a very long way – if the funds "ZMapp" at all acts.
Actually, the Experiments had to take place only later, due to the rapidly spreading Ebola epidemic, with more than 1500 dead in West Africa, they were brought forward, however. "There is an urgent need for a protective Ebola vaccine, and it is important to ensure that vaccination ist" sure;, NIAID Director Anthony Fauci said.
First results before the end of 2014
Tested in the U.S. capital of Washington to be in the vicinity of 20 healthy adults between 18 and 50 years. So, the researchers want to find out whether the vaccine was tested in monkeys, already successful, is safe and what is the reaction of the immune system it causes. During the 48-week test period, participants regularly by a physician. The vaccine is a modified Adenovirus is used as a platform.
In other countries, the product is to be tested in the near future. "The start of Phase-1 vaccine trials against Ebola is the first step in a long Prozess", Fauci stressed. First results are not expected until at least the end of 2014.
100 percent cure animal testing
In the search for an Ebola drug, scientists have achieved in the animal experiment, a 100-percent cure, even in advanced cases. The research group led by Gary Kobinger of the Public Health Agency of Canada announced on Friday its results in the journal "Nature" known. Thus, even those who had only a few more hours to have been healed by the experimental Drug ZMapp all 18 Ebola-infected monkeys. Also severe symptoms such as liver problems, and bleeding have been eliminated by the antibody treatment. The result was "beyond my Erwartungen" Kobinger said.
Guinea variant of the Ebola Virus
The Experiments were performed on animals that were infected with the Kikwit variant of Ebola. It differs from the Guinea variant of the Virus, which is the recent severe outbreak in West Africa. Although the drug was developed by Mapp Biopharmaceutical, based in San Diego has been applied there already as Verzweifelungstat in the fight against the deadly disease. However, the results were not the Doctors, according to a meaningful Two of the Treated were cured, two died. In the laboratory, has shown ZMapp, however, is also effective against the Guinea-strand, which raises hopes for a wider field of application.
Funding is obtained from tobacco leaves
Mapp now has no doses of ZMapp more. The medium is extracted from tobacco leaves in the case of a subsidiary of Reynolds American. A spokeswoman for the group said, a few weeks ago, we have begun with the production of a new Batch. "The process takes Zeit", she said. There should be enough ZMapp is made to the approval procedure for approval of the drug in humans. The appropriate Tests should start by the end of the year.
"ZMapp" bodies, the proteins bind to Ebola-consists of three anti –
Against Ebola, there is currently neither a preventive vaccine nor an approved drug for the treatment of the disease. Several patients in the experimental medium "ZMapp" been administered; some were healed. However, every second Patient survived the moment without this medicine such an infection.
"ZMapp" consists of three antibodies that bind to Ebola proteins. You should enable the immune system to eliminate infected cells. Of the active ingredient that is obtained from a tobacco plant, there were only a few doses. These are awarded according to the world health organization. The production takes months.
The pathogen first appeared – probably at the end of last year – in Guinea, spread to Liberia, then to Sierra Leone, and in July to Nigeria. On Friday, Senegal reported its first case. FOCUS Online/Wochit these are the five most deadly pathogens in the world